

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6952736

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
AVENUE VENTURE OPPORTUNITIES FUND, L.P.	10/05/2021
RECEIVING PARTY DATA	
Name:	STRONGBRIDGE DUBLIN LIMITED
Street Address:	900 NORTHBROOK DRIVE SUITE 200
Internal Address:	ATTN: RICHARD S. KOLLENDER, CHIEF OPERATING OFFICER
City:	TREVOSE
State/Country:	PENNSYLVANIA
Postal Code:	19053
PROPERTY NUMBERS Total: 26	
Property Type	Number
Patent Number:	9198906
Patent Number:	9918984
Patent Number:	10039801
Patent Number:	10098877
Patent Number:	10398751
Patent Number:	10517868
Application Number:	16201410
Application Number:	16205602
Application Number:	16253505
Application Number:	16253515
Application Number:	16512536
Application Number:	16535692
Application Number:	16535704
Application Number:	16540447
Application Number:	16540450
Application Number:	16540456
Application Number:	16540461
Application Number:	16540464
Application Number:	16540468

PATENT

Property Type	Number
Application Number:	16715690
Application Number:	16780057
Application Number:	16863125
Application Number:	62908078
PCT Number:	US2014250
PCT Number:	US1963505
PCT Number:	US1963507

CORRESPONDENCE DATA

Fax Number: (616)742-3999

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6167423945

Email: hkooy@btlaw.com

Correspondent Name: HILLARY KOOY

Address Line 1: 171 MONROE AVE NW, SUITE 1000

Address Line 4: GRAND RAPIDS, MICHIGAN 49503

ATTORNEY DOCKET NUMBER: 82485.2

NAME OF SUBMITTER: HILLARY KOOY

SIGNATURE: /Hillary Kooy/

DATE SIGNED: 10/05/2021

Total Attachments: 7

source=Avenue - Strongbridge - IPSA _ (10.2021) _ executed(21081399.1)#page1.tif

source=Avenue - Strongbridge - IPSA _ (10.2021) _ executed(21081399.1)#page2.tif

source=Avenue - Strongbridge - IPSA _ (10.2021) _ executed(21081399.1)#page3.tif

source=Avenue - Strongbridge - IPSA _ (10.2021) _ executed(21081399.1)#page4.tif

source=Avenue - Strongbridge - IPSA _ (10.2021) _ executed(21081399.1)#page5.tif

source=Avenue - Strongbridge - IPSA _ (10.2021) _ executed(21081399.1)#page6.tif

source=Avenue - Strongbridge - IPSA _ (10.2021) _ executed(21081399.1)#page7.tif

TERMINATION AND RELEASE OF
PATENT AND TRADEMARK SECURITY AGREEMENT

This Termination and Release of Patent and Trademark Security Agreement (this "Termination") dated as of October 5, 2021, is executed by **AVENUE VENTURE OPPORTUNITIES FUND, L.P.**, a Delaware limited partnership, as administrative agent and collateral agent (in such capacity, together with its successors and assigns, the "Secured Party"), and in favor of **STRONGBRIDGE DUBLIN LIMITED**, a private limited company incorporated under the laws of Ireland ("Grantor"). All capitalized terms used in this Termination and not otherwise defined herein, shall have the respective meanings given to such terms in the Patent and Trademark Security Agreement (defined below).

RECITALS

A. The Patent and Trademark Security Agreement, dated as of May 19, 2020, executed by Grantor (as amended, amended and restated, supplemented or otherwise modified from time to time from time to time, the "Patent and Trademark Security Agreement"), was entered into in conjunction with that certain Security Agreement, dated as of May 19, 2020, by and among Secured Party, Grantor and the other Grantors party thereto (as amended, amended and restated, supplemented or otherwise modified from time to time from time to time, the "Security Agreement"), pursuant to which Grantor granted to Secured Party a lien on all of its personal property, including without limitation the patents and patent applications listed on Exhibit A hereto, and the trademarks and trademark applications listed on Exhibit B hereto (such patents, patent applications, trademarks and trademark applications the "Intellectual Property").

B. Pursuant to the Patent and Trademark Security Agreement, Grantor pledged and granted to the Secured Party for the benefit of the Secured Parties (as defined in the Patent and Trademark Security Agreement) a security interest in all of Grantor's right, title and interest in, to and under all of the IP Collateral (as defined below).

C. The Patent and Trademark Security Agreement was recorded with the Trademark Division of the United States Patent and Trademark Office on May 19, 2020, at Reel/Frame 6942/0490, to evidence the security interest granted under the Patent and Trademark Security Agreement.

D. The Patent and Trademark Security Agreement was recorded with the Patent Division of the United States Patent and Trademark Office on May 19, 2020, at Reel/Frame 052705/0039, to evidence the security interest granted under the Patent and Trademark Security Agreement.

E. Secured Party agrees to discharge fully, terminate and release its security interest in the Intellectual Property specified below.

AGREEMENT

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Secured Party hereby agrees as follows:

1. (a) The Patent and Trademark Security Agreement and (b) with respect to the Intellectual Property, the Security Agreement, are hereby terminated and of no further force and effect.

2. Secured Party hereby expressly irrevocably and unconditionally terminates, cancels, fully discharges and releases the security interest pledged and granted by Grantor to the Secured Party in any and all right, title and interest of Grantor in, to and under any and all of the following (the "IP Collateral"), including, without limitation, all of the Intellectual Property, and reassigns, transfers and conveys to Grantor any and all right, title and interest of Secured Party (if any) therein or thereto, including, in each instance, any and all of the foregoing granted to Secured Party pursuant to the Patent and Trademark Security Agreement or Security Agreement:

(a) all patents and patent applications, in each case whether then owned by Grantor or thereafter acquired and whether then existing or thereafter coming into existence, including without limitation those

listed on **Exhibit A**, including the inventions and improvements described and claimed therein together with the reissues, divisions, continuations, renewals, extensions and continuations in part thereof, all income, royalties, damages and payments now or hereafter due and/or payable with respect thereto, all damages and payments for past or future infringements thereof and rights to sue therefor, and all rights corresponding thereto throughout the world; and

(b) all of the trademarks, whether then owned or at any time thereafter acquired, of Grantor that are registered with, or for which applications for registration have been filed with, the United States Patent and Trademark Office, including the trademarks listed on **Exhibit B**, and all registrations and pending applications associated therewith.

3. Secured Party represents and warrants that it has the full power and authority to execute this Termination.

4. Secured Party hereby authorizes the Grantor or its authorized representative to record or file this Termination with the Trademark Division of the United States Patent and Trademark Office, and the United States Copyright Office, at the Grantor's sole cost and expense.

5. Secured Party hereby agrees to duly execute, acknowledge, procure and deliver any further documents and to do such other acts as may be reasonably necessary to effect the termination, release, or reassignment to the Grantor of the security interest contemplated hereby (at the Grantor's sole cost and expense).

6. This Termination and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law shall apply.

[signature on following page]

IN WITNESS WHEREOF, Secured Party has duly executed and delivered this Termination as of the day and year first above written.

SECURED PARTY

AVENUE VENTURE OPPORTUNITIES FUND, L.P.

By: Avenue Venture Opportunities Partners, LLC
Its: General Partner

By: 
Name: Sonia Gardner
Title: Authorized Signatory

[Signature Page to Termination and Release of Patent and Trademark Security Agreement]

DMS 20985912

PATENT
REEL: 057702 FRAME: 0315

EXHIBIT A

PATENTS

COR-003

Title / Owner / Inventor	Country/Number
Methods And Compositions For Treating Diabetes, Metabolic Syndrome And Other Conditions STRONGBRIDGE DUBLIN LIMITED Per Märin	US 9,918,984
	US 10,098,877
	US 10,517,868
	US 16/715,690
Ketoconazole Enantiomer in Humans STRONGBRIDGE DUBLIN LIMITED Timothy Andrew Stewart	US 9,198,906

Exhibit A

COR-005

Title / Owner / Inventor	Country/Number
Pharmaceutical Compositions Of Water Soluble Peptides With Poor Solubility In Isotonic Conditions And Methods For Their Use Strongbridge Dublin Limited Michel Afargan	US 10,039,801
	US 10,398,751
	US 16/512,536

Exhibit A

KEYEYIS

Case Number	Application No.	Filing Date	Title
STRG0001-201T-US	16/201,410	11/27/2018	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0001-201TC1-US	16/780,057	2/3/2020	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0001-201TD1-US	16/535,704	8/8/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-201T-US	16/205,602	11/30/2018	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-201TD1-US	16/540,447	8/14/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-201TD2-US	16/540,450	8/14/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-201TD3-US	16/540,456	8/14/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-201TD4-US	16/540,461	8/14/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-201TD5-US	16/540,464	8/14/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-201TD6-US	16/540,468	8/14/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0003-201T-US	16/253,505	1/22/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0004-201T-US	16/253,515	1/22/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0004-201TC1-US	16/535,692	8/8/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0007-101-US	62/863,125	6/18/2019	DICHLORPHENAMIDE COMPOSITIONS AND METHODS OF USE
STRG0008-101-US	62/908,078	9/30/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0001-401-PC	PCT/US19/63505	11/27/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-401-PC	PCT/US19/63507	1/29/2020	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0004-401-PC	PCT/US20/14250	1/20/2020	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE

Exhibit A

EXHIBIT B
TRADEMARKS

Mark / Owner	Country/Number
STRONGBRIDGE BIOPHARMA STRONGBRIDGE DUBLIN LIMITED	US 5,237,588
RECORLEV STRONGBRIDGE DUBLIN LIMITED	US 5,851,851

Exhibit B